Drug Profile
AQ 13
Alternative Names: Aminoquinolone-13; AQ-13Latest Information Update: 27 Jan 2016
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA); Tulane University
- Developer Immtech Pharmaceuticals
- Class Aminoquinolines; Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 10 Feb 2006 Tulane University has granted Immtech International an exclusive license to develop, manufacture and commercialise aminoquinolones, including AQ 13, for the treatment, prophylaxis and diagnosis of infectious diseases
- 18 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the pharmacokinetics section ,,
- 26 Apr 2000 Phase-I clinical trials for Malaria in USA (PO)